Tag: Biotech and Pharma

FDA advisors recommend Eli Lilly’s Alzheimer’s drug donanemab, paving way for approval

A panel of independent advisors to the Food and Drug Administration on Monday recommended Eli Lilly’s Alzheimer’s drug donanemab, paving the way for the treatment to receive full approval in the U.S. later this year.

GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to proceed

Shares of GSK dropped more than 9% on Monday, after a Delaware judge allowed more than 70,000 lawsuits alleging its discontinued heartburn drug Zantac caused cancer, to go forward, in a blow for the British drugmaker.

Merck could pay up to $3 billion to boost its retinal disease candidate pipeline

Merck & Co. Inc. announced Wednesday an agreement to buy privately held Eyebiotech Ltd., an ophthalmology-focused biotechnology company, in a deal that could be valued at up to $3 billion.

Lavipharm: Εκτίναξη κερδών στο €1,1 εκατ. στο τρίμηνο

Αύξηση κατά 15,9% παρουσιάζουν τα συνολικά κέρδη προ φόρων, τόκων και αποσβέσεων (EBITDA) του Ομίλου της Lavipharm για το Α’ τρίμηνο του 2024, τα οποία διαμορφώθηκαν σε €2,85 εκατ. έναντι €2,46 εκατ. κατά το αντίστοιχο διάστημα του προηγούμενου έτους, σύμφωνα με σχετική ανακοίνωση.

AstraZeneca targets $80 billion in total revenue by 2030 in ‘post-Covid era’

Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023.

Merck KGaA’s Q1 adjusted profit declines less than feared

Merck KGaA on Wednesday reported better-than-expected adjusted earnings, helped by strong demand for its pharmaceuticals and amid currency-adjusted sales growth in semiconductor materials.

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year’s annual ‘Choose France’ business summit.

Novavax shares spike over 100% on Sanofi deal to commercialize Covid vaccine, develop combination shots

Novavax on Friday said it has signed a multibillion-dollar deal with French drugmaker Sanofi to co-commercialize the company’s Covid vaccine starting next year and develop combination shots targeting the coronavirus and the flu, among other efforts. 

AstraZeneca says it will withdraw COVID-19 vaccine globally as demand dips

AstraZeneca said on Tuesday it had initiated the worldwide withdrawal of its COVID-19 vaccine due to a “surplus of available updated vaccines” since the pandemic.

Novo Nordisk beats profit estimates as sales of weight loss drug Wegovy more than double

Novo Nordisk, which became the most valuable company in Europe last year due to the blockbuster success of its weight loss drugs, on Thursday beat first-quarter profit expectations as demand for those medications boomed.

Pfizer beats revenue estimates, raises profit outlook on cost cuts and strong non-Covid sales

Pfizer on Wednesday reported first-quarter revenue that beat expectations and hiked its full-year profit outlook, benefitting from its broad cost-cutting program and strong sales of its non-Covid products.

Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro

Eli Lilly on Tuesday reported first-quarter adjusted profit that topped Wall Street’s expectations and hiked its full-year guidance on strong sales of its blockbuster diabetes drug Mounjaro and newly launched weight loss treatment Zepbound.

Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda

 Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of strong sales for its blockbuster cancer drug Keytruda, sending the company’s shares up more than 2% before the bell.

Ποιες είναι οι νέες πηγές κερδοφορίας για τη Lavipharm

Στις θετικές προοπτικές που διανοίγονται τόσο για φέτος, όσο και για τα επόμενα χρόνια, αναφέρθηκε η διοίκηση της Lavipharm-1,05% στο πλαίσιο της χθεσινής παρουσίασης της εισηγμένης εταιρείας στην Ένωση Θεσμικών Επενδυτών.

Biogen tops profit estimates as cost cuts take hold, Alzheimer’s drug Leqembi launch picks up

Biogen reported first-quarter profit that topped estimates as the company’s cost-cutting efforts took hold and sales of its closely watched Alzheimer’s drug, Leqembi, came in higher than expected.

Drugmaker Novartis climbs 4.4% after guidance rise on sales of blockbuster drugs

Shares of Swiss drugmaker Novartis climbed as much as 4.8% in early deals on Tuesday, after the company raised its full-year guidance following better-than-expected first-quarter results.

Bristol Myers signs $380 mln CAR-T therapies supply deal with Cellares

 Drugmaker Bristol Myers Squibb said it has signed a $380 million deal with contract manufacturer Cellares to manufacture its CAR-T cell therapies in the United States, EU and Japan.

Cardinal Health Won’t Renew OptumRx Distribution Pact. Guidance Is Unchanged.

Shares of Cardinal Health were falling after the drug maker said it won’t be renewing a distribution contract with pharmacy benefits manager OptumRx.

Eli Lilly’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials

Eli Lilly on Wednesday said its highly popular weight loss drug Zepbound showed the potential to treat patients with the most common sleep-related breathing disorder in two late-stage clinical trials.

Johnson & Johnson tops quarterly profit estimates as medical device sales jump

Johnson & Johnson reported first-quarter adjusted earnings that topped expectations as sales in its medical devices business surged.